Theraworx

ApprovedSmall molecule

JJohn Fowler

Theraworx is one of 65 small molecule programs targeting Carpal Tunnel Syndrome. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Carpal Tunnel SyndromeActive, not recruiting

ArthritisActive, not recruiting

Carpal Tunnel SyndromeApproved

Active, not recruiting

ArthritisPhase 3

Active, not recruiting

Competition

Competitive Landscape

159 competitors in Arthritis

#DrugCompanyPhaseTrials

Cosentyx

Novartis

Phase 3

9 2

Simponi

Johnson & Johnson

Phase 3

6 3

Taltz

Eli Lilly

Phase 3

5 4

Aleve

Alnylam Pharmaceuticals

Phase 3

4 5

Stelara

Johnson & Johnson

Phase 3

3 6

Bimzelx

UCB

Phase 3

2 7

Ilaris

Novartis

Phase 3

2 8

Remicade

OOrganon and Co

Phase 3

3 9

Kenalog

BBassett Healthcare

Phase 3

3 10

Kenalog

BBausch Health Americas, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Carpal Tunnel Syndrome1 trial

The Effect of Theraworx Foam in Carpal Tunnel Syndrome

Withdrawn·JJohn Fowler·Phase 4·NCT04017390

Arthritis1 trial

Impact of TheraWorx Foam on Symptom Relief in Thumb Arthritis

Completed·JJohn Fowler·Phase 3·NCT03770091·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Theraworx. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Theraworx compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Theraworx. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — John Fowler company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: JJohn Fowler

Theraworx

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Carpal Tunnel Syndrome1 trial

Arthritis1 trial

References

Drug Info

Quick Facts

Related News